PMID- 31189173
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200612
IS  - 1662-8063 (Electronic)
IS  - 1662-4246 (Print)
IS  - 1662-4246 (Linking)
VI  - 21
IP  - 5-6
DP  - 2018
TI  - Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed 
      Decision-Making for Public Health Precision Medicine.
PG  - 217-227
LID - 10.1159/000500725 [doi]
AB  - BACKGROUND/AIMS: Economic evaluation is integral to informed public health 
      decision-making in the rapidly growing field of precision and personalized 
      medicine (PM); however, this research requires specialized expertise and 
      significant resources. Generic models are a novel innovation to efficiently 
      address a critical PM evidence shortage and implementation barrier by enabling 
      use of population-specific input values. This is a generic PM economic evaluation 
      model proof-of-concept study for a pharmacogenomic use case. METHODS: An 8-step 
      generic economic model development process was applied to the use case of human 
      leukocyte antigen (HLA)-B*15:02genotyping for prediction of carbamazepine-induced 
      cutaneous reactions, with a user-friendly decision-making tool relying on 
      user-provided input values. This generic model was transparently documented and 
      validated, including cross-validation comparing cost-effectiveness results with 3 
      country-specific models. RESULTS: A generic pharmacogenomic use case 
      cost-effectiveness model with decision-making tool was successfully developed and 
      cross-validated using input values for 6 populations which produced consistent 
      results for HLA-B*15:02 screening at country-specific cost-effectiveness 
      threshold values. Differences between the generic and country-specific model 
      results were largely due to differences in model structure and assumptions. 
      CONCLUSION: This proof on concept demonstrates the feasibility of generic models 
      to provide useful PM economic evidence, supporting their use as a pragmatic and 
      timely approach to address a growing need.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - Snyder, Susan R
AU  - Snyder SR
AD  - Department of Epidemiology and Health Services Research, Geisinger Health System, 
      Danville, Pennsylvania, USA, ssnyder@gsu.edu.
FAU - Hao, Jing
AU  - Hao J
AD  - Department of Epidemiology and Health Services Research, Geisinger Health System, 
      Danville, Pennsylvania, USA.
FAU - Cavallari, Larisa H
AU  - Cavallari LH
AD  - Department of Pharmacotherapy and Translational Research, University of Florida, 
      Gainesville, Florida, USA.
FAU - Geng, Zhi
AU  - Geng Z
AD  - Department of Epidemiology and Health Services Research, Geisinger Health System, 
      Danville, Pennsylvania, USA.
FAU - Elsey, Amanda
AU  - Elsey A
AD  - Department of Pharmacotherapy and Translational Research, University of Florida, 
      Gainesville, Florida, USA.
FAU - Johnson, Julie A
AU  - Johnson JA
AD  - Department of Pharmacotherapy and Translational Research, University of Florida, 
      Gainesville, Florida, USA.
FAU - Mohamed, Zahurin
AU  - Mohamed Z
AD  - Department of Pharmacology, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Chaiyakunapruk, Nathorn
AU  - Chaiyakunapruk N
AD  - School of Pharmacy, Monash University Sunway Campus, Subang Jaya, Malaysia.
AD  - Center of Pharmaceutical Outcomes Research (CPOR), Department of Pharmacy 
      Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, 
      Thailand.
AD  - School of Pharmacy, University of Wisconsin, Madison, Wisconsin, USA.
AD  - Asian Centre for Evidence Synthesis in Population, Implementation and Clinical 
      Outcomes (PICO), Global Asia in the 21st Century (GA21) Platform, Monash 
      University, Subang Jaya, Malaysia.
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, Utah, USA.
FAU - Chong, Huey Yi
AU  - Chong HY
AD  - School of Pharmacy, Monash University Sunway Campus, Subang Jaya, Malaysia.
FAU - Dahlui, Maznah
AU  - Dahlui M
AD  - Department of Social and Preventive Medicine, Julius Centre, University of 
      Malaya, Kuala Lumpur, Malaysia.
FAU - Shabaruddin, Fatiha H
AU  - Shabaruddin FH
AD  - Department of Pharmacy, University of Malaya, Kuala Lumpur, Malaysia.
FAU - Patrinos, George P
AU  - Patrinos GP
AD  - University of Patras School of Health Sciences Department of Pharmacy, Patras, 
      Greece.
AD  - United Arab Emirates University, College of Medicine, Department of Pathology, 
      Al-Ain, United Arab Emirates.
FAU - Mitropoulou, Christina
AU  - Mitropoulou C
AD  - The Golden Helix Foundation, London, United Kingdom.
FAU - Williams, Marc S
AU  - Williams MS
AD  - Genomic Medicine Institute, Geisinger Health System, Danville, Pennsylvania, USA.
LA  - eng
GR  - U01 HG007269/HG/NHGRI NIH HHS/United States
PT  - Journal Article
DEP - 20190612
PL  - Switzerland
TA  - Public Health Genomics
JT  - Public health genomics
JID - 101474167
SB  - IM
PMC - PMC6762029
MID - NIHMS1033931
OTO - NOTNLM
OT  - Cost-effectiveness
OT  - Decision analysis
OT  - Modelling
OT  - Pharmacogenomics
OT  - Precision medicine
COIS- Disclosure None of the authors have any disclosures of involvement or commercial 
      associations that might pose or create a conflict of interest with the 
      information presented in this manuscript.
EDAT- 2019/06/13 06:00
MHDA- 2019/06/13 06:01
PMCR- 2020/06/12
CRDT- 2019/06/13 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2019/04/16 00:00 [accepted]
PHST- 2019/06/13 06:00 [pubmed]
PHST- 2019/06/13 06:01 [medline]
PHST- 2019/06/13 06:00 [entrez]
PHST- 2020/06/12 00:00 [pmc-release]
AID - 000500725 [pii]
AID - 10.1159/000500725 [doi]
PST - ppublish
SO  - Public Health Genomics. 2018;21(5-6):217-227. doi: 10.1159/000500725. Epub 2019 
      Jun 12.